ArticleGynecologic oncology2010
Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer.
Article in Gynecologic oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass
Who cites it
61 citing papers in PubMed.
- Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset.BioMed research international · 2015Trial
- Designing early detection programs for ovarian cancer.Annals of oncology : official journal of the European Society for Medical Oncology · 2011Trial
- Construction of a nomogram model for predicting benignity and malignancy in adnexal masses.Ultrasonography (Seoul, Korea) · 2026Article
- Machine Learning-Enhanced Analysis of Exosomal Surface Sialic Acid Using Surface-Enhanced Raman Spectroscopy for Ovarian Cancer Diagnosis and Therapeutic Monitoring.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Circulating proteins and metabolites panel for noninvasive preoperative diagnosis of epithelial ovarian cancer.BMC medicine · 2025Article
- Exhausted and Senescent CD4Diagnostics (Basel, Switzerland) · 2025Article
- sB7-H4 is a diagnostic biomarker in epithelial ovarian cancer and correlates to platinum resistance.Clinical and experimental immunology · 2025Article
- Use of Sensor Array Analysis to Detect Ovarian Cancer through Breath, Urine, and Blood: A Case-Control Study.Diagnostics (Basel, Switzerland) · 2024Article
- Ovarian Cancer surgical consideration is markedly improved by the neural network powered-MIA3G multivariate index assay.Frontiers in medicine · 2024Article
- The value of CA125 in predicting acute complicated colonic diverticulitis.International journal of colorectal disease · 2023Observational
- Nanobodies for the Early Detection of Ovarian Cancer.International journal of molecular sciences · 2022Article
- Review
- Roles of Antimicrobial Peptides in Gynecological Cancers.International journal of molecular sciences · 2022Review
- Recurrence monitoring for ovarian cancer using a cell phone-integrated paper device to measure the ovarian cancer biomarker HE4/CRE ratio in urine.Scientific reports · 2021Article
- A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (Review).International journal of oncology · 2021Review
- CA125 and Ovarian Cancer: A Comprehensive Review.Cancers · 2020Review
- Identifying Ovarian Cancer in Symptomatic Women: A Systematic Review of Clinical Tools.Cancers · 2020Review
- Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.PloS one · 2020Article
- Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review.Journal of ovarian research · 2019Review
- Metastasis in the wild: investigating metastasis in non-laboratory animals.Clinical & experimental metastasis · 2019Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPrior studies suggest that combining the Symptom Index (SI) with a serum HE4 test or a CA125 test may improve prediction of ovarian cancer. However, these three tests have not been evaluated in combination.
methodsA prospective case-control study design including 74 women with ovarian cancer and 137 healthy women was used with logistic regression analysis to evaluate the independent contributions of HE4 and CA125, and the SI to predict ovarian cancer status in a multivariate model. The diagnostic performance of various decision rules for combinations of these tests was assessed to evaluate potential use in predicting ovarian cancer.
resultsThe SI, HE4, and CA125 all made significant independent contributions to ovarian cancer prediction. A decision rule based on any one of the three tests being positive had a sensitivity of 95% with specificity of 80%. A rule based on any two of the three tests being positive had a sensitivity of 84% with a specificity of 98.5%. The SI alone had sensitivity of 64% with specificity of 88%. If the SI index is used to select women for CA125 and HE4 testing, specificity is 98.5% and sensitivity is 58% using the 2-of-3-positive decision rule.
conclusionsA 2-of-3-positive decision rule yields acceptable specificity, and higher sensitivity when all 3 tests are performed than when the SI is used to select women for screening by CA125 and HE4. If positive predictive value is a high priority, testing by CA125 and HE4 prior to imaging may be warranted for women with ovarian cancer symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.